

---



---

## LIST OF TABLES

Table	Page
<b>Table (1):</b> The structure and function of SLE antigens -----	7
<b>Table (2):</b> Clinical associaton of autoantibodies in SLE -----	7
<b>Table (3):</b> American College of Rheumatology Revised Classification Criteria for Systemic Lupus Erythematosus-----	8
<b>Table (4):</b> Opposing effects of antiphospholipid antibodies on coagulation -----	19
<b>Table (5):</b> 2006 preliminary criteria for the classification of definite antiphospholipid syndrome -----	22
<b>Table (6):</b> Clinical manifestations of antiphospholipid syndrome -----	24
<b>Table (7):</b> Comparison between the studied groups according to demographic data -----	40
<b>Table (8):</b> Comparison between the patients according to Disease duration -----	42
<b>Table (9):</b> Comparison between the studied groups according to clinical manifestations-----	44
<b>Table (10):</b> Comparison between the studied groups according to complications -----	46
<b>Table (11):</b> Comparison between the studied groups according to medications received -----	49
<b>Table (12):</b> Comparison between the studied groups according to anti-dsDNA and ANA-----	50
<b>Table (13):</b> Comparison between the studied groups according to Prothrombin Time and aPTT -----	52
<b>Table (14):</b> Comparison between the studied groups according to CBC -----	55
<b>Table (15):</b> Comparison between the studied groups according to renal function -----	59
<b>Table (16):</b> Comparison between the studied groups according to urine analysis -----	61
<b>Table (17):</b> Comparison between the studied groups according to antibeta2 glycoprotein-----	63
<b>Table (18):</b> Comparison between the studied groups according to lupus anticoagulant, anticardiolipin antibodies IgM and IgG -----	66
<b>Table (19):</b> Sensitivity, specificity and accuracy for antibeta2 Glycoprotein (IgM and IgG) and Anticardiolipin antibodies (IgM and IgG) with control group and SLE + antiphospholipid -----	69

---

<b>Table (20):</b>	Sensitivity, specificity and accuracy for antibeta2 Glycoprotein (IgM and IgG) and Anticardiolipin antibodies (IgM and IgG) with control and SLE-----	70
<b>Table (21):</b>	Correlation between antibeta2 Glycoprotein IgM and IgG with different parameters in SLE + APS group-----	71
<b>Table (22):</b>	Correlation between antibeta2 Glycoprotein IgM and IgG with different parameters in SLE group-----	73
<b>Table (23):</b>	Correlation between antibeta2 Glycoprotein IgM and IgG with clinical manifestations in SLE + APS group-----	75
<b>Table (24):</b>	Correlation between antibeta2 Glycoprotein IgM and IgG with clinical manifestations in SLE group-----	76
<b>Table (25):</b>	Correlation between antibeta2 Glycoprotein IgM and IgG and complications in SLE + APS group-----	77
<b>Table (26):</b>	Correlation between antibeta2 Glycoprotein IgM and IgG and complications in SLE group-----	78

---



---

## LIST OF FIGURES

Figure	Page
<b>Figure (1):</b> Pathogenesis of systemic lupus erythematosus -----	5
<b>Figure (2):</b> Some clinical features of SLE -----	9
<b>Figure (3):</b> Pathogenesis of antiphospholipid syndrome-----	12
<b>Figure (4):</b> How cardiolipin triggers apoptosis -----	14
<b>Figure (5):</b> Cardiolipin serves as a trap in oxidative phosphorylation-----	15
<b>Figure (6):</b> Lupus Anticoagulant-----	16
<b>Figure (7):</b> Two views, related by 180° rotation of the electrostatic potential surface of $\beta_2$ -GPI. The molecule has five distinct domains-----	18
<b>Figure (8):</b> Phospholipid involvement in the coagulation pathway-----	20
<b>Figure (9):</b> Potential sites of action of antibodies in APS -----	20
<b>Figure (10):</b> Antiphospholipid antibodies pathogenic mechanisms mediating thrombosis-----	21
<b>Figure (11):</b> Major characteristics of APS include: deep vein thrombosis, pulmonary emboli, myocardial infarction, stroke, livedo reticularis, heart valve disease, recurrent abortions, skin ulcers, impaired blood supply to the fingers, Budd-Chiari syndrome, and small vessel disease of the kidneys -----	25
<b>Figure (12):</b> A diagram representing the clinical manifestations in 1000 patients having APS. The common clinical manifestations are thrombosis, strokes, pregnancy failure, involvement of blood system, heart injury, and in addition damage to the lungs, eyes, kidneys, skin, joints, bones and abdominal viscera -----	26
<b>Figure (13):</b> Comparison between the studied groups according to age-----	41
<b>Figure (14):</b> Comparison between the studied groups according to sex -----	41
<b>Figure (15):</b> Comparison between the studied groups according to disease duration---	42
<b>Figure (16):</b> Comparison between the studied groups according to clinical manifestation-----	45
<b>Figure (17):</b> Comparison between the studied groups according to complications -----	47
<b>Figure (18):</b> Comparison between the studied groups according to medications received -----	49
<b>Figure (19):</b> Comparison between the studied groups according to anti-dsDNA -----	51

---

---

<b>Figure (20):</b> Comparison between the studied groups according to ANA-----	51
<b>Figure (21):</b> Comparison between the studied groups according to Prothrombin Time-----	53
<b>Figure (22):</b> Comparison between the studied groups according to aPTT -----	53
<b>Figure (23):</b> Comparison between the studied groups according to haemoglobin -----	56
<b>Figure (24):</b> Comparison between the studied groups according to WBCs -----	56
<b>Figure (25):</b> Comparison between the studied groups according to platelets -----	57
<b>Figure (26):</b> Comparison between the studied groups according to albumin/creat. Ratio-----	60
<b>Figure (27):</b> Comparison between the studied groups according to antibeta2 glycoprotein IgM -----	64
<b>Figure (28):</b> Comparison between the studied groups according to antibeta2 glycoprotein IgG-----	64
<b>Figure (29):</b> Comparison between the studied groups according to lupus anticoagulant-----	67
<b>Figure (30):</b> Comparison between the studied groups according to anticardiolipin antibodies IgM-----	68
<b>Figure (31):</b> Comparison between the studied groups according to anticardiolipin antibodies Ig-----	68
<b>Figure (32):</b> Correlation between antibeta2 Glycoprotein IgM and IgG with platelets in SLE + antiphospholipid group -----	72
<b>Figure (33):</b> Correlation between antibeta2 Glycoprotein IgM and IgG with partial thromboplastin time in SLE group-----	74

---

## LIST OF ABBREVIATIONS

<b>aCL</b>	: Anticardiolipin
<b>ACR</b>	: American College of Rheumatology
<b>ANA</b>	: Antinuclear antibody
<b>Anti-dsDNA</b>	: Anti-double stranded deoxyribonucleic acid
<b>Anti-RNA</b>	: Anti-ribonucleic acid
<b>Anti-Ro</b>	: Anti rodent
<b>Anti-Sm ab</b>	: Anti-Smith antibody
<b>Anti-<math>\beta_2</math>GP1</b>	: Anti-beta <sub>2</sub> glycoprotein 1
<b>APS</b>	: Antiphospholipid syndrome
<b>aPTT</b>	: activated partial thromboplastin time
<b>BCR</b>	: B cell antigen receptor
<b>BILAG</b>	: British Isles Lupus Assessment Group
<b>Blys</b>	: B lymphocyte stimulator
<b>CAPS</b>	: Catastrophic antiphospholipid syndrome
<b>DIL</b>	: Drug induced lupus
<b>dPT</b>	: Diluted prothrombin time
<b>dRVVT</b>	: Diluted Russell's viper venom
<b>DVT</b>	: Deep vein thrombosis
<b>EBV</b>	: Epstein-barr virus
<b>Ec</b>	: Endothelial cell
<b>ECLAM</b>	: European Consensus Lupus Activity Measure
<b>ELISA</b>	: Enzyme linked immunosorbent assay
<b>HDL</b>	: High Density Lipoprotein
<b>HRP</b>	: Horseradish peroxidase
<b>ICAM-1</b>	: Intracellular adhesion molecule-1
<b>IFN</b>	: Interferon
<b>IL</b>	: Interleukin

---

<b>ISTH</b>	: International Society of Thrombosis and Haemostasis
<b>ITAM</b>	: Immuno-tyrosine activation motif
<b>KCT</b>	: Kaolin clotting time
<b>LAC</b>	: Lupus anticoagulant
<b>LAI</b>	: Lupus Activity Index
<b>mDCs</b>	: Myeloid dendritic cells
<b>NETs</b>	: Neutrophil extracellular traps
<b>NPSLE</b>	: Neuropsychiatric systemic lupus erythematosus
<b>PBS</b>	: Phosphate buffer saline
<b>pDCs</b>	: Plasmacytoid dendritic cells
<b>PF4-HC</b>	: Platelet factor 4–heparin complex
<b>PS</b>	: Phosphatidylserine
<b>SCLE</b>	: Subacute cutaneous lupus
<b>SLE</b>	: Systemic lupus erythematosus
<b>SLEDAI</b>	: Systemic Lupus Erythematosus Disease Activity Index
<b>SLICC</b>	: Systemic Lupus International Collaborating Clinics
<b>ssDNA</b>	: Single stranded deoxyribonucleic acid
<b>TLR</b>	: Toll-like receptor
<b>TMB</b>	: Tetramethyl benzidine
<b>TNF</b>	: Tumor necrosis factor